AC Immune SA
The mission of AC Immune is to identify and develop “best in class” innovative therapies for Alzheimer´s Disease and other conformational diseases.
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s Disease drug development. We are developing innovative therapeutics with “best in class” potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
03.12.2024
Biotech startups celebrate new achievements (startupticker.ch)
24.09.2024
Financial boost for five publicly traded companies (startupticker.ch)
30.08.2024
US and European approvals open new avenues for Swiss Biotechs (startupticker.ch)
30.07.2024
AC Immune receives FDA Fast Track Designation for Alzheimer’s Disease (startupticker.ch)
13.05.2024
AC Immune inks billion-dollar deal with Takeda (startupticker.ch)
No milestones
No Jobs
No videos and documents
IMD Startup Competition
The IMD Startup Competition provides an unique opportunity for regional technology startups to benefit from the help and insights of a team of dedicated, experienced IMD participants from the MBA and the Executive MBA programs.
AC Immune SA
The mission of AC Immune is to identify and develop “best in class” innovative therapies for Alzheimer´s Disease and other conformational diseases.
Website:
www.acimmune.com/
Headquarter:
Lausanne
Foundation Date:
February 2003
Technology:
- Biotech
Sectors:
- Drug discovery